News AZ takes Medicare negotiation appeal to SCOTUS AstraZeneca has elevated its challenge to Medicare drug price negotiation powers to the Supreme Court of the US.
News Acadia, Harmony record late-stage rare disease failures Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.
News Moderna opens UK facility as drug pricing spat rumbles on The UK government has celebrated the opening of Moderna's £150m vaccines facility, but storm clouds continue to gather on the issue of drug pricing.
News Joy as uniQure Huntington's therapy clears pivotal trial uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.
News BMS eyes filings for myeloma 'celmod' iberdomide Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.
News MSD's $349m alliance with Variational, and other AI news MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.
News Activist investor renews its criticism of Novavax Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a "destruction in shareholder value."
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
